We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 364

Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • November 5 2017

Judge Patti B. Saris denied the Bank of New York Mellon’s (BNY Mellon) motion to strike putative class representative Ashby Henderson. BNY Mellon


Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • September 27 2017

The U.S. Supreme Court resolved a circuit split by deciding that the three-year limit for filing lawsuits under Section 13 of the Securities Act is a


AbbVie Files BPCIA Suit Against Boehringer Ingelheim Over Humira (Adalimumab)
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 16 2017

Recently, AbbVie, Inc. and AbbVie Biotechnology, LTD (collectively “AbbVie” or “Plaintiffs”) filed a Complaint in the United States District Court


JPML Refuses MDL for Proton Pump Inhibitor Kidney Injury Cases
  • Reed Smith LLP
  • USA
  • March 7 2017

A Multidistrict Litigation (MDL) can be a sound way of managing a mass tort. Efficiencies are available (e.g., deposing company witnesses only once


Preamble Expressing the Intended Result of a Method of Treatment Is Not Limiting
  • McDermott Will & Emery
  • USA
  • November 11 2016

In construing a claim involving a method for treating obesity, the US District Court for the District of Delaware determined that a phrase in the


"Key Takeaways: Fourth Annual Seminar for Pharmaceutical, Biotechnology and Medical Device Companies"
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • October 24 2016

On October 5, 2016, Skadden hosted its Fourth Annual Seminar for Pharmaceutical, Biotechnology and Medical Device Companies. The seminar focused on


Disregard of Speculative Financial Projections Was Not Bad Faith
  • Morris James LLP
  • USA
  • June 1 2016

In a stockholder challenge to a sale of the company, a plaintiff may rebut the business judgment rule by pleading facts that support a reasonable


Inside the Courts: An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • May 31 2016

Judge John L. Kane reaffirmed a prior ruling certifying a class of investors in the Oppenheimer California Municipal Bond Fund who alleged claims


Delaware Court of Chancery Holds that Board’s Decision to Disregard Speculative Projections Did Not Support Claim of Bad Faith
  • Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • USA
  • May 25 2016

In In re Chelsea Therapeutics International Ltd. Stockholder Litigation, the Court of Chancery dismissed claims that the board of a target company


Chelsea TherapeuticsCourt of Chancery Dismisses Claims that Directors Breached Fiduciary Duties by Not Utilizing Certain Management Projections
  • Fried Frank Harris Shriver & Jacobson LLP
  • USA
  • May 24 2016

The Delaware Court of Chancery's decision in Chelsea Therapeutics Stockholder Litigation (May 20, 2016) underscores the benefits of disclosure to